Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
ثبت نشده
چکیده
©2017 Blue Cross and Blue Shield of Louisiana An independent licensee of the Blue Cross and Blue Shield Association No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana. Page 1 of 12 Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.
منابع مشابه
Microarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Criteria for the diagnosis, staging, and response assessment of multiple myeloma have been reported by the International Myeloma Working Group and are in widespread use.(12,14,16) The decision to treat is based on criteria set forth in the diagnosis of multiple myeloma, which includes serum hypercalcemia, renal dysfunction, anemia and bone lesions (i.e., CRAB). Patients with monoclonal gammopat...
متن کاملMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Multiple myeloma is a genetically complex, invariably fatal, neoplasm of plasma cells. Cytogenetic and other laboratory tests identify markers to classify newly diagnosed multiple myeloma patients into high, intermediate and standard clinical risk categories. The level of risk reflects the aggressiveness of the disease, and thus dictates the intensity of initial treatment. Thus, a riskadapted a...
متن کاملMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
1. The technology must have final approval from the appropriate government regulatory bodies; 2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes; 3. The technology must improve the net health outcome; 4. The technology must be as beneficial as any established alternatives; 5. The improvement must be attainable outside the investigationa...
متن کاملMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
IMPORTANT REMINDER Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence. PLEASE NOTE: Contracts exclude fro...
متن کاملMicroarray-Based Gene Expression Profile Testing for Multiple Myeloma Risk Stratification
Prior Authorization Information Pre-service approval is required for all inpatient services for all products. See below for situations where prior authorization may be required or may not be required for outpatient services. Yes indicates that prior authorization is required. No indicates that prior authorization is not required. N/A indicates that this service is primarily performed in an inpa...
متن کامل